Iterum Therapeutics (NASDAQ:ITRM) Earns Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Iterum Therapeutics (NASDAQ:ITRMFree Report) in a research note released on Monday morning, Benzinga reports. The brokerage currently has a $6.00 target price on the stock.

Iterum Therapeutics Price Performance

NASDAQ ITRM opened at $1.55 on Monday. Iterum Therapeutics has a 52 week low of $0.62 and a 52 week high of $2.50. The firm has a market capitalization of $20.82 million, a P/E ratio of -0.52 and a beta of 2.36. The company has a quick ratio of 2.35, a current ratio of 2.35 and a debt-to-equity ratio of 3.63. The company has a 50-day moving average price of $1.51 and a 200-day moving average price of $1.40.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ITRM. Goldman Sachs Group Inc. bought a new position in shares of Iterum Therapeutics during the 2nd quarter valued at approximately $61,000. Renaissance Technologies LLC grew its stake in shares of Iterum Therapeutics by 199.1% during the 2nd quarter. Renaissance Technologies LLC now owns 323,300 shares of the company’s stock valued at $65,000 after acquiring an additional 215,200 shares during the period. Finally, Dimensional Fund Advisors LP bought a new position in Iterum Therapeutics in the 3rd quarter worth approximately $101,000. 9.21% of the stock is currently owned by institutional investors.

About Iterum Therapeutics

(Get Free Report)

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.

Featured Stories

Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with's FREE daily email newsletter.